These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 14645868)

  • 1. Infliximab cost-effectiveness/safety?
    Rothschild BM
    Rheumatology (Oxford); 2003 Dec; 42(12):1572-3; author reply 1573-4. PubMed ID: 14645868
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result.
    Welsing PM; Severens JL; Laan RF
    Rheumatology (Oxford); 2003 Dec; 42(12):1574-5; author reply 1573-4. PubMed ID: 14645870
    [No Abstract]   [Full Text] [Related]  

  • 3. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective coverage and reimbursement strategies for etanercept and infliximab in the treatment of rheumatoid arthritis.
    Sokol MC
    Manag Care Interface; 2005 Apr; 18(4):32-7. PubMed ID: 15889761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
    Welsing PM; Severens JL; Hartman M; van Riel PL; Laan RF
    Arthritis Rheum; 2004 Dec; 51(6):964-73. PubMed ID: 15593319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis: out of touch with clinical reality?
    Maetzel A
    Arthritis Rheum; 2005 Feb; 53(1):3-4. PubMed ID: 15696549
    [No Abstract]   [Full Text] [Related]  

  • 7. Etanercept or infliximab: the patient's considerations.
    Sherrick RC
    Arch Intern Med; 2006 Jul; 166(13):1418; author reply 1418. PubMed ID: 16832010
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab (Rituxan) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment.
    Laas K; Peltomaa R; Kautiainen H; Puolakka K; Leirisalo-Repo M
    Ann Rheum Dis; 2006 Jul; 65(7):924-8. PubMed ID: 16339293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rheumatoid arthritis: early aggressive therapy including biologicals -- pro].
    Rubbert-Roth A
    Dtsch Med Wochenschr; 2005 Aug; 130(33):1900. PubMed ID: 16118736
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
    van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
    Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing model structures in cost-effectiveness analysis.
    Russell LB
    Med Decis Making; 2005; 25(5):485-6. PubMed ID: 16160203
    [No Abstract]   [Full Text] [Related]  

  • 14. Rate and causes of infliximab discontinuation in patients with rheumatoid arthritis in a private clinical practice.
    Bertoli AM; Strusberg I; Baravalle M; Betelu Z; Calás D; Morales L; Strusberg AM
    J Clin Rheumatol; 2008 Dec; 14(6):313-7. PubMed ID: 18690164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nesiritide--not verified.
    April PA
    N Engl J Med; 2005 Oct; 353(14):1525-7; author reply 1525-7. PubMed ID: 16211707
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of rituximab in refractory cold agglutinin disease.
    Panwar U; Mathews C; Cullis JO
    Int J Lab Hematol; 2008 Aug; 30(4):331-3. PubMed ID: 18665831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
    Kobelt G; Andlin-Sobocki P; Maksymowych WP
    J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of biologics in early rheumatoid arthritis.
    Finckh A; Bansback N; Liang MH
    Ann Intern Med; 2010 Mar; 152(5):333-4; author reply 334. PubMed ID: 20194244
    [No Abstract]   [Full Text] [Related]  

  • 19. Not all "quality-adjusted life years" are equal.
    Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
    J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.